Updated June 2022

OHSU Parkinson Center Research Opportunities

The OHSU Parkinson Center is a national leader in Parkinson's disease (PD) research and is involved in many studies that are fully recruited and others that are being planned.

Please note: You may not personally benefit from participating in a research study. However, by service as a subject, you may help us learn how to benefit patients in the future.

Research Database

Title: Department of Neurology Research Contact & Health Information Repository (NeuroNEXT)

Purpose: This research database allows staff to collect information about patients who are willing to consider participation in upcoming clinical research projects.

Participation Requirements:

- You are age 18 or older
- You are willing to provide health information to research staff
- You have a neurological diagnosis **OR** you do not have a neurological diagnosis

Participation details: You will be asked to complete an Informed Consent Form, which allows research staff to include your information in the research database. The form asks for information about your health history, medications, and the types of research that may interest you. Completing the consent form does not mean you have agreed to participate in a specific study, but you are giving research staff authorization to include your health information in the database for future reference. When a study is starting and we are looking for eligible participants, we will search through the database to find people who fit the profile for the study. If your information matches, study staff will contact you to discuss the study in further detail and ask if you are interested in participating.

For more information: contact study staff at (503) 418-4387 or PDResearch@ohsu.edu and reference IRB #8049 in your message. **(OHSU eIRB #8049)**

Newly Diagnosed with Parkinson's Disease

Have you been diagnosed with Parkinson's disease in the last 3 years and are not currently taking carbidopa/levodopa or dopamine agonists?

Purpose: This study explores the ability of K0706, an experimental drug, to slow the progression of Parkinson's disease (PD). K0706 aims to block an enzyme called "Abl" which may play a role in PD. There are currently no drugs available proven to slow the progression of PD.

Participation Requirements: In order to participate in the study you must have been diagnosed with PD within the last 3 years, are older than 50 years of age, and have no history of taking dopaminergic drugs for more than 30 days previously. You must be able to have an MRI and DaT SPECT.

Participation Details: Study participation occurs over a period of 44 weeks and includes 11 visits to OHSU if deemed eligible after an up to six week screening period. Visits occur every 2 to 8 weeks. If enrolled, you will take K0706 in powder form mixed with a glass of water once daily and record your daily dose in a journal. This study is placebo-controlled, meaning that you may receive a placebo instead of study drug. Eligible participants will receive study-related evaluations at no cost, possibly including an MRI and DaT SPECT. Participants are compensated for their time and travel after visits are completed.

For more information please contact study staff at PDResearch@ohsu.edu and reference #20122 in the subject line. (eIRB #20122)

Have you been diagnosed with Parkinson's disease (PD) within the past 3 years but have not started taking PD medications?

Title: Study in Parkinson's Disease of Exercise Phase 3 Clinical Trial (SPARX3)
Purpose: SPARX3 is a research study to learn more about the effects of aerobic exercise on people with Parkinson's disease who have not yet started medication for their PD. It will compare the effects of moderate

intensity treadmill exercise to high intensity treadmill exercise on the signs and symptoms of Parkinson's disease.

Participation requirements: We are seeking subjects who satisfy the following criteria:

- Between 40 and 80 years of age
- Diagnosed with primary PD with disease duration less than 3 years
- Has not yet started medication for PD
- Not likely to begin dopaminergic therapy within the next 6 months

Participation details: First, you will complete two screening visits to confirm that you meet the criteria to participate in the study. These visits consist of physical and memory/thinking assessments, a blood draw for exercise clearance, a questionnaire to screen for depression, and a brain scan (DaTscan) that helps confirm diagnosis of PD. These screening activities are explained in further detail below.

If you are eligible to participate in this study, you will then complete a series of visits, which consist of more physical and memory/thinking assessments, questionnaires, blood draws, exercise tests, and brain scans. You will also be randomized (like flipping a coin) to one of two exercise groups. You will be asked to exercise, at a specific rate/intensity, 4 days per week for approximately 30 min, while we will closely monitor you. Your participation in this study, including study visits and the exercise sessions will last approximately 2 years (24-26 months).

For more information, please contact: Austin Prewitt at 503-418-2600 E: prewitta@ohsu.edu. (eIRB# 21483)

General Parkinson's and Parkinsonism Studies

Would you want to participate in a Parkinson's research study from your home?

Title: Trial of Parkinson's And Zoledronic Acid

Purpose: The primary aim of the study is to evaluate the efficacy of a single infusion of zoledronic acid to reduce the risk of clinical fractures in Parkinson's Disease or neurodegenerative parkinsonism.

Participation requirements:

- You are 60 years or older
- You have Parkinson's Disease or neurodegenerative parkinsonism diagnosis (including progressive supranuclear palsy, multiple system atrophy, cortical basal degeneration, vascular parkinsonism, dementia with Lewy bodies or another form of neurodegenerative parkinsonism)
- You do not have a history of hip fracture
- No use of a biphosphate drug within the last 12 months
- You are able to walk without the assistance of another person

Participation details: This study involves one visit at your home which is conducted by a nurse that will perform the infusion of either the medication or the placebo. Following that time, you will receive a phone call approximately every four months checking to see your current status.

For more information please contact: Morgan Wilhelmi at (503) 494-7235, PDResearch@ohsu.edu, or wilhelmo@ohsu.edu.

IRB#22788

Are you interested in genetic testing?

Title: PDGENEration
Purpose: To create a genetic data and sample repository for Parkinson's disease for future research use.

Participation requirements:

- Willingness to share and bank residual DNA samples extracted from buccal swab for future research use.
- Willingness to deposit data obtained from genetic testing results for PD related genes to the Parkinson's Foundation data repository.
- Willingness to be recontacted in the future for research studies and updates research information.

Participation details: This study involves one visit either in our clinic or at home. You will be asked to complete a buccal (cheek) swab at that time. The swab will be sent for genetic testing for 7 known genes linked to PD.

For more information please contact: The study coordinator team at PDResearch@ohsu.edu
IRB# 22841

Memory and Cognition

Have you been diagnosed with Alzheimer's disease, mild cognitive impairment, another type of dementia, OR are healthy and would like to participate in research?

Title: Peptide Biomarkers for Alzheimer's disease
Purpose: The purpose of this study is to see if biological molecules in the blood and cerebrospinal fluid (CSF) can help detect Alzheimer's disease (and other types of dementia) at an earlier stage.

Participation requirements:

- You are between 55 and 80 years old
- You are a healthy volunteer (no neurological diagnosis), or have a diagnosis of AD, mild cognitive impairment, Parkinson's disease, fronto-temporal dementia, or dementia with Lewy Bodies.
- You have a study partner who will attend study visits with you.
- You are not taking warfarin or other blood thinners.
- You have no lower back problems and/or surgeries.

Participation details: This study involves collection of blood from a vein in your arm, and collection of CSF through a lumbar puncture (spinal tap). There are two study visits over approximately 1 month and one follow up phone call. You will receive study-related evaluations at no cost and will be compensated $100 for time and transportation for the lumbar puncture visit.

For more information please contact: Morgan Wilhelmi at (503) 494-7235, PDResearch@ohsu.edu, or wilhelmo@ohsu.edu
IRB #18193

Are you interested in participating in a study to learn more about role of genes in thinking and memory in Parkinson's disease?

Title: Pacific Northwest UDALL Center (PANUC): Clinical Core and Sample Collection
Purpose: This study aims to characterize the changes in thinking and memory of Parkinson's disease patients over time and to determine the role genetics plays in cognitive impairment in Parkinson's disease.

Participation requirements:

- You have a diagnosis of Parkinson's disease or you are willing to participate as a healthy volunteer.

Participation Details: This is a long-term study and your participation would last 5 years or more. The study involves at least two visits to the VA Portland Health Care System. At each visit, you will undergo tests of thinking and memory, have a neurological exam, fill out questionnaires, and have a blood draw. Each visit will last for about three to four hours. After the first visit, you have the option to undergo a lumbar puncture. A lumbar puncture is known as a spinal tap. A spinal tap is where a special needle is inserted between bones in your back and fluid is removed. The spinal tap will take about two to two and a half hours. You have the option to undergo a second spinal tap three years after the first spinal tap. In between visits at the VAPORHCS you will have a telephone interview with questions regarding your thinking and memory. These interviews will last about 30 minutes. You will be compensated $200.00 for each spinal tap that you complete.

For more information please contact: Micki Le at (503) 220-8262 x54688 or by mail at 3710 SW US Veterans Road, Portland, Oregon 97239. IRB#6154, MIRB #2332

Balance & Gait Studies

Do you have a Parkinson's disease diagnosis and no falls over the last 12 months?

Title: Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation
Purpose: This study involves wearing mobility sensors at home for one week to learn about mobility patterns in people with Parkinson's disease (PD).

Participation requirements:

- You are 55-85 years old with Parkinson's disease
- You have not experienced any falls in the last 12 months
- You can walk for two minutes unassisted
- You are taking a stable dose of Levodopa medication
- Willing to wear mobility sensors for two, 1-week periods and track your falls for 12 months

- You have no other neurological or musculoskeletal issues

Participation details: If you decide to take part in this study, you would be asked to wear a set of mobility monitoring sensors for one week and to track your falls for one year through email survey. The sensors collect information about your balance and mobility and are worn on the feet and around the waist (3 total sensors) for up to 10 hours per day for 7 days. Participants will also be asked to complete several surveys and questionnaires during two separate virtual visits or during a single in-person visit with study staff members. Participants repeat the week with mobility monitoring sensors and the study visits after the 12-months of fall tracking are complete. Participants are compensated $200 for completing the study in its entirety. This study can be completed in person or entirely virtual/remote.

For more information, please contact: Jacquie Ellison 503-418-2601. IRB#: 18978

Have you received a Parkinson's disease diagnosis and experiences at least one fall over the last 12 months?

Title: Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation
Purpose: This study aims to learn more about the effectiveness of an exercise boot camp program to improve mobility and decrease falls in individuals with Parkinson's disease.

Participation requirements:

- You are 55-85 years old with Parkinson's disease
- You have experienced at least one fall in the last 12 months
- You can walk for two minutes unassisted
- You are taking a stable dose of Levodopa medication
- Willing to wear mobility sensors for 1 week and track your falls for 12 months
- Able to take part in a 6-week exercise intervention depending on randomization
- You have no other neurological or musculoskeletal issues

Participation details: If you decide to take part in this study, you would be randomly assigned to either an exercise intervention or a control group. Participants in the exercise intervention group attend 3 exercise sessions per

week for 6 weeks, while the control group is asked to maintain their existing exercise routine for the same 6-week period. Participants in both groups are asked to wear a set of mobility monitoring sensors for three, 1-week periods and to track their falls for one year through automated email surveys. The sensors collect information about your balance and mobility and are worn on the feet and around the waist (3 total sensors) for up to 10 hours per day for 7 days. Several surveys, questionnaires, and assessments are completed during three in-person study visits. Participants are compensated $300 or $450 (depending on randomization) for completing the study.

For more information, please contact: Jacquie Ellison 503-418-2601. IRB#: 18978

Motor Fluctuations with Carbidopa/Levodopa

The Effect of GOCOVRI on Quantity and Quality of Gait in Parkinson's Disease IRB# 20105, PI: Amie Hiller

This study is investigating the effect of GOCOVRI (extended release Amantadine) on activity levels in people with Parkinson's disease that experience Levodopa induced dyskinesia (LID). The study includes 2 remote/virtual visits and two 1-week periods of home monitoring with wearable sensors and medication tracking. Participants will take GOCOVRI for a total of 5 weeks. We are looking for people ages 50-70 years old that have idiopathic Parkinson's disease and at least 1 hour/day of ON time with Levodopa induced dyskinesia, no other neurological or musculoskeletal disorders, and no renal impairments. For more information, please contact Graham Harker harkerg@ohsu.edu / 503-418-2601. This study is virtual/remote.

STAT-PD: Preventing Levodopa Induced Dyskinesia in Parkinson's disease with HMG-CoA Reductase Inhibitors (OHSU eIRB # 17302; MIRB # 3869)

Almost all PD patients will develop involuntary movements overtime with treatment of levodopa. This study involves two visits. The first visit, a screening visit, will happen at the VA Portland Health Care System or virtually (over the internet) and last about two hours. During this visit you will complete some questionnaires, answer some questions about your Parkinson's disease and have a physical examination. The second visit will happen at Oregon Health & Science University and will last 8 to 9 hours depending on your levodopa cycle. You will arrive in the morning at 08:00 am in an "OFF" state. You will eat breakfast. You will undergo various measures of your Parkinsonism, movements, and answer

more questionnaires about how Parkinson's affects you. You will receive an intravenous levodopa infusion from 09:30 am to 11:30 am. Every half hour starting at 09:00 am, we will measure your movements, Parkinsonism, and complete some questionnaires. The study visit will last until 03:00 pm or when you turn "OFF". You will receive $10 for the screening visit and $50 for completing the all-day visit, for a total of $60 compensation. You may not personally benefit from participating in this study. However, by service as a subject, you may help us learn how to benefit patients in the future. For more information on how to participate, please contact Brenna Lobb, Research Coordinator, at (503) 220 – 8262 extension 51871 or by mail at 3710 SW US Veterans Rd, P3-PADRECC, Portland, Oregon 97239.

Huntington's Disease

Have you been diagnosed with Huntington's disease and are willing to participate in research on the stress hormone, cortisol?

Title: Measuring Cortisol Levels in Persons with Parkinson's (PD) [CORT-PD]
Purpose: Cortisol is a hormone that is normally released in response to events and circumstances such as waking up in the morning, exercising, and stress.

Participation requirements:

- You have been diagnosed with Parkinson's disease, Huntington's disease, or are willing to participate as a healthy volunteer.
- You are willing to give saliva samples.

Participation Details: This study will last about 1 week. There are two paths for participation. Option 1 has three (3) days of saliva collection at home and one visit to the Portland VA (VA Portland Health Care System). Option 2 has two visits to the Portland VA. Visit one will last approximately 30 minutes and include questionnaires of mood and quality of life. For PD and HD participants, a disease specific exam will be performed. You will collect your saliva, complete some diaries, and wear some sensors for three days at home. You will return to the Portland VA for a visit that lasts about five minutes to return the sensors, diaries, and saliva. The visit will last approximately 30 minutes and include

questionnaires of mood and quality of life. You will be compensated $25.00 for participation in this study. We will reimburse travel expenses up to $50.00 round trip.

For more information please contact: Brenna Lobb at (503) 220-8262 extension 51871 or lobbb@ohsu.edu.

IRB #15183

Spinocerebellar Ataxia

Have you been diagnosed with Spinocerebellar Ataxia (SCA) type 1, 2, 3, or 6 or Friederich's Ataxia (FA)?

Title: APDM Instrumented Data Exchange for Ataxia (IDEA)
Purpose: The purpose of this research study is to establish and standardize an efficient methodology for objective measures of movement disorders in ataxia using wearable inertial sensors and to demonstrate their utility for clinical trials in these diverse degenerative cerebellar disorders. Our long-term goal is a global suite of measurements that are convenient to obtain in the course of a routine clinical exam as well as daily life monitoring assessments of mobility disability to facilitate and support adequately powered clinical trials.

Participation requirements:

- SCA 1, 2, 3, 6, and FA with mutations in the pathogenic range confirmed from genetic testing.
- SCA: aged 18-75 **OR** FA: aged 18-30, diagnosed between ages 5-25.
- community dwelling.
- physically/cognitively capable of consenting (or assenting, in the case of children, and permission of at least one parent) and complying with the protocol based on investigator's judgement.
- able to walk independently 10 ft without an assistive device.
- able to sit or stand unassisted for 30 seconds.
- no other neurological or musculoskeletal disorder that could affect mobility, except as designated by group.
- no history of head injury, vestibular function, stroke or other disorders that could affect mobility.

Participation details: This study requires 5 visits to the Balance Disorders Laboratory and will take 2 years to complete. If you decide to participate, you will be asked complete a number of tests and procedures at each study visit:

- Undergo a neurological exam to verify diagnosis (for ataxia subjects) and any other
  medical problems you may have (at each visit)
- Complete several questionnaires about your health
- Undergo clinical tests of your balance with and without wearing movement sensors.
- Perform a 25-foot and 2-minute walk tests
- Wear sensors during daily-life for 7 days

For more information, please contact: Austin Prewitt at 503-418-2600 E: prewitta@ohsu.edu or Graham Harker at 503-418-2601 E: harkerg@ohsu.edu for more information. (eIRB# 21082)

Progressive Supranuclear Palsy (PSP)

Have you been diagnosed with progressive supranuclear palsy (PSP)?

Title: Cerebellar Transcranial Magnetic Stimulation for Motor Control in Progressive Supranuclear Palsy
Purpose: To investigate whether transcranial magnetic stimulation (TMS) effective for treating issues with balance and speech in progressive supranuclear palsy (PSP).

Participation requirements:

- Age 40-85
- You have been diagnosed with supranuclear palsy (PSP)
- You are willing to refrain from other physical and speech therapy programs for the duration for the study
- You are able to remain on stable doses of medications for the duration of the study
- You do not have any other significant neurological disorders (including seizures) or inner ear disorders.
- You do not have medical implants (such as a pacemakers, defibrillators, or cochlear implants) or material containing metal in your eyes, head, or body

Participation details: This study involves 24 total visits that may include balance and gait testing, an MRI scan of the brain, cognitive testing, and TMS or a “sham” treatment.

For more information, please contact: Austin Prewitt at prewitta@ohsu.edu or 503-418-2600.
IRB #66152

Multiple Sclerosis (MS)

Physical fatigue in Multiple Sclerosis

Title: Neuro-correlates of Fatigue in Multiple Sclerosis
Purpose: This study aims to understand how the brain is involved in motor fatigue (a decline in a person's ability to exert force) in people with Multiple Sclerosis (MS) and how fatigue impacts balance during standing and walking.

Participation requirements:

- Age 18-65 (with a focus on MS participants less than 35 years old)
- You are a healthy volunteers or volunteer with MS
- You are able to perform two 6-min walks.
- You have no other neurological or musculoskeletal issues and are not participating in any exercise program specific to balance

Participation details: Participation includes an MRI scan of the brain, balance testing, brief nerve stimulation behind one leg, and strength testing of the low leg muscles. This is a single visit lasting about 3.5 hours. You will be compensated $40 for time and transportation. Interested participants can start the screening process by filling out the screening questionnaire at this link: https://is.gd/msfatigue. Eligible participants will receive a call or email.

For more information, please contact: Austin Prewitt at prewitta@ohsu.edu or 503-418-2600.
IRB#: 18714

Healthy Control

Have you been diagnosed with Alzheimer's disease, mild cognitive impairment, another type of dementia, OR are healthy and would like to participate in research?

Title: Peptide Biomarkers for Alzheimer's Disease

Purpose: The purpose of this study is to see if genes and biomarkers in the blood

and cerebrospinal fluid (CSF) can help detect Alzheimer's disease (AD) at an earlier stage. Researchers would like to learn more about specific types of genes and biomarkers in blood and CSF to help understand the biology of AD. If a gene or genes that cause AD can be found, the diagnosis and treatment of AD may be improved.

Participation Requirements:

- You are 55-80 years old
- You have a diagnosis of Parkinson's disease, Alzheimer's Disease, fronto-temporal dementia, dementia with Lewy Bodies or no neurological diagnosis
- You are in good health
- You have someone willing to attend study visits with you
- You are taking warfarin or other blood thinners
- You have lower back problems/surgeries

Participation details: This study involves collection of blood from a vein in your arm, and collection of CSF through a lumbar puncture (spinal tap). There are two study visits over approximately 1 month. Eligible participants will receive study-related evaluations at no cost. Participants will be compensated for their time and transportation for the lumbar puncture visit.

For more information, please contact Morgan Wilhelmi at (503) 494-7235, PDResearch@ohsu.edu or wilhelmo@ohsu.edu. eIRB #18193

Other Parkinson's disease research studies can be found at these sites:
Michael J Fox Trial Finder: https://foxtrialfinder.michaeljfox.org
National Institutes of Health: https://clinicaltrials.gov
Washington State PD Registry: www.registerparkinsons.org

The OHSU Parkinson Center is recognized as a Parkinson's Foundation Center of Excellence.

Parkinson's Foundation
CENTER OF EXCELLENCE